Albert Oriol
About
Albert Oriol is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Albert Oriol has authored 313 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 257 papers in Hematology, 173 papers in Oncology and 140 papers in Molecular Biology. Recurrent topics in Albert Oriol's work include Multiple Myeloma Research and Treatments (227 papers), Protein Degradation and Inhibitors (112 papers) and Peptidase Inhibition and Analysis (69 papers). Albert Oriol is often cited by papers focused on Multiple Myeloma Research and Treatments (227 papers), Protein Degradation and Inhibitors (112 papers) and Peptidase Inhibition and Analysis (69 papers). Albert Oriol collaborates with scholars based in Spain, United States and France. Albert Oriol's co-authors include Josep‐María Ribera, María‐Victoria Mateos, Jesús F. San Miguel, Evarist Feliú, Joan Bladé, Juan José Lahuerta, Philippe Moreau, Laura Rosiñol, Jesús María Hernández‐Rivas and Javier de la Rubia and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Albert Oriol
302 papers receiving 6.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Albert Oriol Spain | 41 | 4.8k | 3.2k | 3.1k | 1.2k | 991 | 313 | 6.9k | ||
| Jordi Esteve Spain | 43 | 4.9k 1.0× | 2.6k 0.8× | 1.8k 0.6× | 1.6k 1.3× | 1.8k 1.8× | 262 | 7.6k | ||
| Joseph Brandwein Canada | 40 | 2.7k 0.6× | 1.8k 0.6× | 1.8k 0.6× | 1.2k 1.0× | 1.0k 1.0× | 191 | 5.3k | ||
| Giuseppe Avvisati Italy | 43 | 5.0k 1.0× | 4.1k 1.3× | 1.5k 0.5× | 987 0.8× | 922 0.9× | 202 | 7.5k | ||
| Patrizia Tosi Italy | 35 | 5.2k 1.1× | 3.6k 1.1× | 3.0k 1.0× | 400 0.3× | 1.0k 1.0× | 146 | 6.6k | ||
| Ingemar Turesson Sweden | 46 | 6.2k 1.3× | 4.0k 1.2× | 3.5k 1.1× | 322 0.3× | 1.8k 1.8× | 148 | 8.3k | ||
| Meir Wetzler United States | 48 | 5.0k 1.0× | 3.0k 0.9× | 2.1k 0.7× | 1.9k 1.6× | 2.1k 2.1× | 245 | 8.6k | ||
| Gérald Marit France | 43 | 5.9k 1.2× | 3.3k 1.0× | 3.3k 1.0× | 905 0.7× | 2.2k 2.2× | 193 | 8.6k | ||
| Christian Récher France | 49 | 5.0k 1.0× | 4.4k 1.4× | 1.9k 0.6× | 1.1k 0.9× | 1.8k 1.8× | 299 | 9.1k | ||
| Roy B. Jones United States | 43 | 3.4k 0.7× | 970 0.3× | 2.5k 0.8× | 880 0.7× | 1.2k 1.2× | 176 | 6.6k | ||
| Norbert Ifrah France | 52 | 7.3k 1.5× | 3.9k 1.2× | 3.5k 1.1× | 2.8k 2.3× | 1.7k 1.7× | 231 | 11.4k |
Countries citing papers authored by Albert Oriol
Since
Specialization
Citations
This map shows the geographic impact of Albert Oriol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Oriol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Oriol more than expected).
Fields of papers citing papers by Albert Oriol
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Albert Oriol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Oriol. The network helps show where Albert Oriol may publish in the future.
Co-authorship network of co-authors of Albert Oriol
This figure shows the co-authorship network connecting the top 25 collaborators of Albert Oriol. A scholar is included among the top collaborators of Albert Oriol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Oriol. Albert Oriol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Quach, Hang, Gurdeep Parmar, Enrique M. Ocio, et al.. (2024). A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica. 109(12). 4078–4082.
2.
Oriol, Albert, et al.. (2023). Evolution of Pharmacological Treatments and Associated Costs for Multiple Myeloma in the Public Healthcare System of Catalonia: A Retrospective Observational Study. Cancers. 15(22). 5338–5338.
3.
Cohen, Yaël C., Daniel Morillo, Moshe E. Gatt, et al.. (2023). POSTER: MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S226–S226.
4.
Xicoy, Blanca, Jordi Juncà, Lurdes Zamora, et al.. (2022). Optimization of monocyte gating to quantify monocyte subsets for the diagnosis of chronic myelomonocytic leukemia. Cytometry Part B Clinical Cytometry. 104(4). 319–330.
5.
Trotman, Judith, Christian Buske, Alessandra Tedeschi, et al.. (2021). Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial. Clinical Cancer Research. 27(21). 5793–5800.
6.
Dimopoulos, Meletios Α., Ivan Špıčka, Hang Quach, et al.. (2020). Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. Journal of Clinical Oncology. 38(34). 4030–4041.
7.
Puig, Noemí, Luís A. Corchete, Julio Dávila, et al.. (2020). Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. Cancers. 12(12). 3615–3615.
8.
Ocio, Enrique M., Paula Rodríguez‐Otero, Joaquín Martínez‐López, et al.. (2020). Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. British Journal of Haematology. 192(3). 522–530.
9.
Medaglia, Alice Annalisa, Ajay K. Nooka, Nizar J. Bahlis, et al.. (2020). Dreamm-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (rrmm). SHILAP Revista de lepidopterología.
10.
Cohen, Yaël C., Albert Oriol, Ka Lung Wu, et al.. (2020). Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21(1). 46–54.e4.
11.
Oriol, Albert, Eugènia Abella, María Teresa Cibeira, et al.. (2020). Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma. Leukemia & lymphoma. 62(1). 125–135.
12.
Lonial, Sagar, Jesús F. San Miguel, Joaquín Martínez‐López, et al.. (2017). Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study. Blood. 130. 1869–1869.
13.
Brighton, Timothy, Simon J. Harrison, David Ghez, et al.. (2017). A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma. Blood. 130. 3155–3155.
14.
Dimopoulos, Meletios Α., Albert Oriol, Hareth Nahi, et al.. (2016). An open-label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX. 101.
15.
Dimopoulos, Meletios Α., Antonio Palumbo, Paolo Corradini, et al.. (2015). THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA. Haematologica. 100. 83–83.
16.
Morgan, Gareth J., Antonio Palumbo, Sujith Dhanasiri, et al.. (2014). Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM ‐003 trial for pomalidomide plus low‐dose dexamethasone. British Journal of Haematology. 168(6). 820–823.
17.
Weisel, Katja, Meletios Α. Dimopoulos, Michèle Cavo, et al.. (2014). Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010). Blood. 124(21). 4755–4755.
18.
Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Pilar Giraldo, et al.. (2013). Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine. 369(5). 438–447.
19.
Kantarjian, Hagop M., Xavier Thomas, Anna Dmoszyńska, et al.. (2012). Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology. 30(21). 2670–2677.
20.
Navarro, José‐Tomás, José‐Ángel Hernández‐Rivas, Josep‐María Ribera, et al.. (1998). Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.. PubMed. 83(11). 998–1000.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jordi Esteve Breakdown of academic impact, for papers by Joseph Brandwein Breakdown of academic impact, for papers by Giuseppe Avvisati Breakdown of academic impact, for papers by Patrizia Tosi Breakdown of academic impact, for papers by Ingemar Turesson Breakdown of academic impact, for papers by Meir Wetzler Breakdown of academic impact, for papers by Gérald Marit Breakdown of academic impact, for papers by Christian Récher Breakdown of academic impact, for papers by Roy B. Jones Breakdown of academic impact, for papers by Norbert Ifrah